Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DL-3-n-butylphthalide for Chemotherapy-Induced Cognitive Impairment
NCT06508671Phase 4Not yet recruiting
- Sponsor
- First Hospital of China Medical University
- Start
- Jul 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
01
Overview
A Phase 4 trial of butylphthalide in chemotherapy-induced cognitive impairment (CICI), sponsored by First Hospital of China Medical University. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
butylphthalide
03
Conditions
chemotherapy-induced cognitive impairment (CICI)
Beyond the preview
Go deeper on NCT06508671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06508671.